Shots:
- Generate Biomedicines and Zealand Pharma entered a strategic collaboration to develop multispecific protein therapeutics for obesity and other metabolic diseases using Generate’s generative AI platform and Zealand Pharma’s metabolic health expertise
- Under the agreement, Generate will receive $30M upfront, up to $35M in early preclinical milestones, and is eligible for nearly $1.2B including potential development, regulatory, and commercial milestones, plus tiered royalties on worldwide net sales for the two initial programs
- Generate will lead research through lead-candidate selection, while Zealand Pharma will oversee subsequent clinical development, regulatory submissions, and worldwide commercialization. The agreement also includes an option to add a third program
Ref: Generate Biomedicines | Image: Generate Biomedicines and Zealand Pharma | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
